about
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.High fragmentation characterizes tumour-derived circulating DNA.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.Circulating tumor-derived DNA is shorter than somatic DNA in plasma.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancerThe Value of Cell-free DNA for Molecular Pathology.Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats.A phylogenetic latent feature model for clonal deconvolutionEnhanced detection of circulating tumor DNA by fragment size analysisDetection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patientsMeasurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft modelsCirculating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsComprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumorsToward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNActDNA monitoring using patient-specific sequencing and integration of variant reads
P50
Q33911932-04BCE930-DC56-42E5-8480-1D5B6E864C63Q34016528-C7BE4E1A-7937-4CDF-A527-52B0596EBA88Q35127938-888CF0F4-049C-44E7-8054-3306ECCB962EQ35212453-4210F177-AC25-4A04-92CB-B755253C1945Q36865058-4A7957E0-24C9-46CA-B79C-67E6AB0747F8Q38010746-347C89CF-69D2-4774-8591-360BB7DA50EFQ39149201-E005B420-F3BB-44C7-94D8-712A76ABFDEBQ40022390-2BF550AE-1468-47D2-AF57-572D90FE07F8Q41134871-81691EC7-1AF9-4A00-91C1-9F5DAC27EDA6Q48143437-866BDF7F-CDE6-4DF5-BE23-0E1573E7330DQ49145768-890A79F6-D5D3-45EB-BD42-1291FC9D5529Q56687889-076BBDF7-ECB4-47CD-B2EA-1C63BC243D39Q58602903-801C6351-3826-4696-9D1C-13C62A5273B2Q58606619-59B2A051-93CD-4129-A722-5CB632520695Q58615751-D5CFB47F-2375-4196-A57A-5BC20157070BQ58704645-2D44121F-0487-457B-99B3-3FB711BDF761Q89945283-9111ECD2-43DF-45B3-8DC1-00D7BF1F47BCQ90718257-252F5C7C-2AAF-41B0-8790-DC88633908E0Q96591156-5610388E-920F-42AD-80F2-40FE918D9C2C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Florent Mouliere
@ast
Florent Mouliere
@en
Florent Mouliere
@es
Florent Mouliere
@nl
Florent Mouliere
@sl
type
label
Florent Mouliere
@ast
Florent Mouliere
@en
Florent Mouliere
@es
Florent Mouliere
@nl
Florent Mouliere
@sl
prefLabel
Florent Mouliere
@ast
Florent Mouliere
@en
Florent Mouliere
@es
Florent Mouliere
@nl
Florent Mouliere
@sl
P106
P1153
36630830500
P21
P31
P496
0000-0001-7043-0514